Surgical Oncology Liver Tumor Conference Series

---

RSS

Occurs weekly every Tuesday starting on 1/1/2025 at 5:00 PM
Wednesday, January 1, 2025, 5:00 PM - 6:00 PM, Virtual, Houston, TX


AMA PRA Category 1 Credits™ (1.00 hours), AAPA Category 1 CME (1.00 hours), ABS CC (1.00 hours), Non-Physician Attendance (1.00 hours)

This series will address improvements in multiple and varied treatment options for patients with Hepatocellular Carcinoma, as well as address indeterminate or undiagnosed liver lesions which can lead to delayed or sub-optimal treatment strategies. This series will also discuss rare biliary or liver tumors protocols, as there is a lack of standard treatment strategies.

1. Interpret imaging studies and histological/pathological findings for most common hepatobiliary tumors.
2. Implement multidisciplinary treatment recommendations for patients with complex hepatobiliary malignancies.
3. Apply multidisciplinary consensus practice guidelines in diagnosis and treatment of patients with hepatobiliary malignancies.
4. Demonstrate best practice outcomes via case studies of patients with complex hepatobiliary tumors.

This is a closed, invitation only series. 

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

 

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Date	Empty Column	Title
7/15/2025 5:00:00 PM	Surgical Oncology Liver Tumor Conference Series - 7/15/2025 7/15/2025 5:00:00 PM 7/15/2025 6:00:00 PM 11 Virtual False MM/DD/YYYY	Surgical Oncology Liver Tumor Conference Series - 7/15/2025 This series will address improvements in multiple and varied treatment options for patients with Hepatocellular Carcinoma, as well as address indeterminate or undiagnosed liver lesions which can lead to delayed or sub-optimal treatment strategies. This series will also discuss rare biliary or liver tumors protocols, as there is a lack of standard treatment strategies. Objective(s): 1 Interpret imaging studies and histological/pathological findings for most common hepatobiliary tumors. 2 Implement multidisciplinary treatment recommendations for patients with complex hepatobiliary malignancies. 3 Apply multidisciplinary consensus practice guidelines in diagnosis and treatment of patients with hepatobiliary malignancies. 4 Demonstrate best practice outcomes via case studies of patients with complex hepatobiliary tumors. Location: Virtual Specialties: Diagnostic Radiology, Radiation Oncology, Colon and Rectal Surgery, Complex General Surgical Oncology Faculty Disclosures: Jean Nicolas Vauthey, MD (Nothing to disclose - 10/09/2024) Yun Shin Chun, MD (Nothing to disclose - 05/22/2025) Download Handout Location: Virtual Specialties: Colon and Rectal Surgery, Complex General Surgical Oncology, Diagnostic Radiology, Radiation Oncology
7/22/2025 5:00:00 PM	Surgical Oncology Liver Tumor Conference Series - 7/22/2025 7/22/2025 5:00:00 PM 7/22/2025 6:00:00 PM 11 Virtual False MM/DD/YYYY	Surgical Oncology Liver Tumor Conference Series - 7/22/2025 This series will address improvements in multiple and varied treatment options for patients with Hepatocellular Carcinoma, as well as address indeterminate or undiagnosed liver lesions which can lead to delayed or sub-optimal treatment strategies. This series will also discuss rare biliary or liver tumors protocols, as there is a lack of standard treatment strategies. Objective(s): 1 Interpret imaging studies and histological/pathological findings for most common hepatobiliary tumors. 2 Implement multidisciplinary treatment recommendations for patients with complex hepatobiliary malignancies. 3 Apply multidisciplinary consensus practice guidelines in diagnosis and treatment of patients with hepatobiliary malignancies. 4 Demonstrate best practice outcomes via case studies of patients with complex hepatobiliary tumors. Location: Virtual Specialties: Diagnostic Radiology, Radiation Oncology, Colon and Rectal Surgery, Complex General Surgical Oncology Faculty Disclosures: Jean Nicolas Vauthey, MD (Nothing to disclose - 10/09/2024) Yun Shin Chun, MD (Nothing to disclose - 05/22/2025) Download Handout Location: Virtual Specialties: Colon and Rectal Surgery, Complex General Surgical Oncology, Diagnostic Radiology, Radiation Oncology